Non-Hodgkin's Lymphoma
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog.
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the latest news and research items in this category.
Arborizing vessels under dermoscopy: a case of cellular neurothekeoma instead of basal cell carcinoma.
Abstract
Neurothekeoma is a slow-growing, benign tumor of nerve sheath origin. Herein we present a 62-year-old female who presented with a 5-month history of a nodule that had shown a slight enlargement. She had a diagnosis of non-Hodgkin lymphoma for 10 years for which she had received multiple sessions of chemotherapy and radiotherapy. Cutaneous examination showed a well-defined, firm, 2 cm, pink-red nodule of the right supraclavicular area, which showed thick and arborizing vessels under dermoscopy. A diagnosis of cellular neurothekeoma was made after histopathologic examination with immunohistochemistry. Thick ...
Source: Dermatol Online J - May 25, 2013 Category: Dermatology Authors: Aydingoz IE, Mansur AT, Dikicioglu-Cetin E Tags: Dermatol Online J Source Type: research
Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
Conclusion: We conclude that bortezomib resulted in rapid and dramatical responses regardless of the line of therapy. Although most of these responses were not sustained, bortezomib represents a new therapeutic option for PBL that should be further explored in larger clinical trials.
PMID: 23689224 [PubMed - in process] (Source: Onkologie)
Source: Onkologie - May 24, 2013 Category: Cancer & Oncology Authors: Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, Safah H Tags: Onkologie Source Type: research
[Articles] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
R-CHOP-14 is not superior to R-CHOP-21 chemotherapy for previously untreated diffuse large B-cell lymphoma; therefore, R-CHOP-21 remains the standard first-line treatment in patients with this haematological malignancy. No molecular or clinical subgroup benefited from dose intensification in this study. (Source: LANCET)
Source: LANCET - May 24, 2013 Category: Journals (General) Authors: David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M Ardeshna, John A Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David Linch Tags: Articles Source Type: research
[Comment] Therapy for diffuse large B-cell lymphoma: getting personal
In 1979, Jones and colleagues showed that CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) was superior to CVP (cyclophosphamide, vincristine, and prednisone) in treatment of patients with diffuse lymphomas. This early report probably included patients with not only what is currently called diffuse large B-cell lymphoma but also other distinct lymphoproliferative disorders including T-cell non-Hodgkin lymphoma and mantle cell lymphoma. Despite repeated attempts to improve the efficacy of CHOP in patients with diffuse large B-cell lymphoma by addition of other cytotoxic drugs, or by syncopating or alternati...
Source: LANCET - May 24, 2013 Category: Journals (General) Authors: Bruce D Cheson Tags: Comment Source Type: research
Atrazine and nitrate in public drinking water supplies and non-hodgkin lymphoma in nebraska, USA.
Abstract
A secondary analysis of 1999-2002 Nebraska case-control data was conducted to assess the risk of non-Hodgkin lymphoma (NHL) associated with exposure to nitrate- and atrazine-contaminated drinking water. Water chemistry data were collected and weighted by well contribution and proximity of residence to water supply, followed by logistic regression to determine odds ratios (OR) and 95% confidence intervals (CI). We found no association between NHL risk and exposure to drinking water containing atrazine or nitrate alone. Risk associated with the interaction of nitrate and atrazine in drinking water was elevat...
Source: Environmental Health Insights - May 24, 2013 Category: Environmental Health Authors: Rhoades MG, Meza JL, Beseler CL, Shea PJ, Kahle A, Vose JM, Eskridge KM, Spalding RF Tags: Environ Health Insights Source Type: research
Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.
Abstract
The effective antitumorigenic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) and eicosonoid (EP; EP1-4) receptor antagonists prompted us to test their efficacy in Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) related lymphomas. Our study demonstrated that (1) EP1-4 receptor protein levels vary among the various non-Hodgkin's lymphoma (NHL) cell lines tested (BCBL-1:KSHV+/EBV-;BC-3: KSHV+/EBV-; Akata/EBV+: KSHV-/EBV+; and JSC-1 cells: KSHV+/EBV + cells); (2) 5.0 μM of EP1 antagonist (SC-51322) had a significant antiproliferative effect on BCBL-1, BC-3, Akata/EBV+...
Source: Translational Research : the journal of laboratory and clinical medicine - May 23, 2013 Category: Laboratory Medicine Authors: Paul AG, Chandran B, Sharma-Walia N Tags: Transl Res Source Type: research
Pesticide use and non-Hodgkin's lymphoma mortality in Brazil.
CONCLUSION: Our results suggest that pesticide exposure may play a role in the etiology of NHL.
PMID: 23602533 [PubMed - in process] (Source: International Journal of Hygiene and Environmental health)
Source: International Journal of Hygiene and Environmental health - May 22, 2013 Category: Environmental Health Authors: Boccolini Pde M, Boccolini CS, Chrisman Jde R, Markowitz SB, Koifman S, Koifman RJ, Meyer A Tags: Int J Hyg Environ Health Source Type: research
Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use.
CONCLUSIONS: We found little evidence that the use of TCAs increases the risk of NHL overall or for specific common subtypes of NHL.
PMID: 23683711 [PubMed - in process] (Source: Annals of Epidemiology)
Source: Annals of Epidemiology - May 22, 2013 Category: Epidemiology Authors: Lowry SJ, Chubak J, Press OW, McKnight B, Weiss NS Tags: Ann Epidemiol Source Type: research
Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use
Conclusions: We found little evidence that the use of TCAs increases the risk of NHL overall or for specific common subtypes of NHL. (Source: Annals of Epidemiology)
Source: Annals of Epidemiology - May 21, 2013 Category: Epidemiology Authors: Sarah J. Lowry, Jessica Chubak, Oliver W. Press, Barbara McKnight, Noel S. Weiss Source Type: research
Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation
Conclusions
About half of transplant-eligible patients with transformation are able to undergo ASCT. Outcomes following ASCT appear to have improved over recent years, although the role of rituximab in this patient population requires further evaluation. (Source: Annals of Oncology)
Source: Annals of Oncology - May 21, 2013 Category: Cancer & Oncology Authors: Villa, D., Crump, M., Keating, A., Panzarella, T., Feng, B., Kuruvilla, J. Tags: hematologic malignancies Source Type: research
Pfizer halts study of lymphoma drug unlikely to help survival
(Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Radiotherapy Is NOT Essential to Cure Diffuse Large B-Cell Non-Hodgkin Lymphoma
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news
[Non-Hodgkin lymphoma of maxillofacial soft tissue: A report of two cases and review of the literature.]
We report two cases of maxillofacial soft tissue non-Hodgkin lymphoma treated with chemotherapy followed by localized radiotherapy with complete remission after 3 and 6 months. We study the clinical, radiological and histopathological features as well as the treatment and the prognosis of extranodal non-Hodgkin lymphomas maxillofacial muscles.
PMID: 23665292 [PubMed - as supplied by publisher] (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - May 9, 2013 Category: Cancer & Oncology Authors: Chaabouni S, Ben Salah Lahiani H, Ghorbel L, Abdelmoula M, Elloumi M, Daoud J Tags: Cancer Radiother Source Type: research
Occupational exposure to trichloroethylene and perchloroethylene and the risk of lymphoma, liver, and kidney cancer in four Nordic countries
Conclusions
Although this study was subject to limitations related to the low prevalence of exposure to PER and TCE in the Nordic population and a limited exposure assessment strategy, we observed some evidence indicative of an excess risk of cancer of the liver and NHL in subjects exposed to PER. (Source: Occupational and Environmental Medicine)
Source: Occupational and Environmental Medicine - May 8, 2013 Category: Occupational Health Authors: Vlaanderen, J., Straif, K., Pukkala, E., Kauppinen, T., Kyyronen, P., Martinsen, J. I., Kjaerheim, K., Tryggvadottir, L., Hansen, J., Sparen, P., Weiderpass, E. Tags: Cancer Workplace Source Type: research
Should the Paradigm Shift for Low-Grade Follicular Non-Hodgkin Lymphoma Be Toward Less Therapy? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 7, 2013 Category: Cancer & Oncology Authors: Haines Tags: CORRESPONDENCE Source Type: research
The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study
Conclusions:
This study provides new information on the expression of different MMPs and VEGF in canine lymphoma, suggesting a possible correlation between different MMPs and VEGF, immunophenotype and prognosis. (Source: BMC Veterinary Research - Latest articles)
Source: BMC Veterinary Research - Latest articles - May 3, 2013 Category: Veterinary Research Authors: Arianna AricòMery GiantinMaria GelainFulvio RiondatoStefano ComazziBarbara RütgenSabine EsslerMauro DacastoMassimo CastagnaroLuca Aresu Source Type: research
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of newly diagnosed lymphomas and has an overall cure rate of approximately 60%. Previously, we observed FOXO1 mutations in non-Hodgkin lymphoma patient samples. To explore the effects of FOXO1 mutations, we assessed FOXO1 status in 279 DLBCL patient samples and 22 DLBCL-derived cell lines. FOXO1 mutations were found in 8.6% (24/279) of DLBCL cases: 92.3% (24/26) of mutations were in the first exon, 46.2% (12/26) were recurrent mutations affecting the N-terminal region, and another 38.5% (10/26) affected the Forkhead DNA binding domain. Recurrent mutations in the...
Source: Blood - May 2, 2013 Category: Hematology Authors: Trinh, D. L., Scott, D. W., Morin, R. D., Mendez-Lago, M., An, J., Jones, S. J. M., Mungall, A. J., Zhao, Y., Schein, J., Steidl, C., Connors, J. M., Gascoyne, R. D., Marra, M. A. Tags: Lymphoid Neoplasia Source Type: research
Non-Hodgkin's lymphoma
This article will give an overview of lymphoid neoplasms, concentrating on the common subtypes of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Clinical outcomes in B-cell NHL have significantly improved in the past decade, largely due to the availability of the monoclonal antibody, rituximab. However, some aggressive lymphomas, including many T-cell disorders, still carry a poor prognosis. (Source: Medicine)
Source: Medicine - May 1, 2013 Category: Internal Medicine Authors: Lisa Lowry, David Linch Tags: Lymphoproliferative disorders Source Type: research
Diagnosing Diffuse Large B-Cell Non-Hodgkin Lymphoma by Endoscopic Ultrasound-Fine-Needle Aspiration of a Splenic Mass [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 26, 2013 Category: Cancer & Oncology Authors: El-Majzoub, Kharfan-Dabaja, Boulos, Mahfouz, Eloubeidi Tags: Diagnosis & Staging, CT, Ultrasound DIAGNOSIS IN ONCOLOGY Source Type: research
What Is the Role of Stem-Cell Transplantation for Follicular Non-Hodgkin Lymphoma in the Rituximab Era? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 26, 2013 Category: Cancer & Oncology Authors: Schouten Tags: Lymphoma, Chemotherapy EDITORIALS Source Type: research
Tracheomediastinal Fistula Caused by Non-Hodgkin's Lymphoma.
Abstract
Non-Hodgkin's lymphoma involving the tracheobronchial tree is uncommon. A 60-year-old man presented with severe cough for two months. Bronchoscopy disclosed an ulcerative lesion at the lower trachea and carina with anterior tracheomediastinal fistula, and biopsy revealed tracheal wall B-cell lymphoma. After chemo-radiotherapy, the tracheomediastinal fistula healed, but eight months later, tracheal stenosis was diagnosed by bronchoscopy. A self-expansible metallic stent was placed, which successfully maintained the airway.
PMID: 23603637 [PubMed - as supplied by publisher] (Source: Annals of Thoracic an...
Source: Annals of Thoracic and Cardiovascular Surgery - April 20, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Huang CL, Chen HC, Huang HC, Cheng CY Tags: Ann Thorac Cardiovasc Surg Source Type: research
Breast Schwannoma With Diffuse Large B-Cell LymphomaBreast Schwannoma With Diffuse Large B-Cell Lymphoma
Was there a connection between this patient's non-Hodgkin's lymphoma and her breast mass? Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients
& Carlos E Bacchi (Source: Modern Pathology AOP)
Source: Modern Pathology AOP - April 19, 2013 Category: Pathology Authors: Ívison X DuartePollyanna Domeny-DuarteSheila CL WludarskiYasodha NatkunamCarlos E Bacchi Tags: follicular lymphoma immunohistochemistry indolent lymphoma non-Hodgkin lymphoma survival young adults Source Type: research
Predictors of Use of Complementary and Alternative Medicine by Non-Hodgkin Lymphoma Survivors and Relationship to Quality of Life
Conclusions. CAM use may be related to more positive mental health–related quality of life by increasing patients’ perception of perceived control over their health; however, cause and effect cannot be determined. Physicians should be aware that cancer survivors have a need to take an active role in improving their health. (Source: Integrative Cancer Therapies)
Source: Integrative Cancer Therapies - April 18, 2013 Category: Cancer & Oncology Authors: Hamilton, A. S., Miller, M. F., Arora, N. K., Bellizzi, K. M., Rowland, J. H. Tags: Articles Source Type: research
Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence
Probability of event-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is about 80%, whereas survival in relapsed patients is very poor. No stratification criteria have been established so far. Recently, activating NOTCH1 mutations were reported to be associated with favorable prognosis, and loss of heterozygosity at chromosome 6q (LOH6q) was reported to be associated with increased relapse risk. The current project was intended to evaluate the prognostic effect of these markers. Mutations in hot spots of NOTCH1 and FBXW7 were analyzed in 116 patients. Concerning LOH6q status, 118 patients were investigated, ...
Source: Blood - April 18, 2013 Category: Hematology Authors: Bonn, B. R., Rohde, M., Zimmermann, M., Krieger, D., Oschlies, I., Niggli, F., Wrobel, G., Attarbaschi, A., Escherich, G., Klapper, W., Reiter, A., Burkhardt, B. Tags: Pediatric Hematology, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008
Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of cytotoxic chemotherapy. Despite major changes in cancer treatment, data describing tAML risks over time are sparse. Among 426 068 adults initially treated with chemotherapy for first primary malignancy (9 US population-based cancer registries, 1975-2008), we identified 801 tAML cases, 4.70 times more than expected in the general population (P < .001). Over time, tAML risks increased after chemotherapy for non-Hodgkin lymphoma (n = 158; Poisson regression Ptrend < .001), declined for ovarian cancer (n = 72; Ptrend < .001), myel...
Source: Blood - April 11, 2013 Category: Hematology Authors: Morton, L. M., Dores, G. M., Tucker, M. A., Kim, C. J., Onel, K., Gilbert, E. S., Fraumeni, J. F., Curtis, R. E. Tags: Free Research Articles, Myeloid Neoplasia Source Type: research
Imaging of Burkitt's lymphoma-abdominal manifestations
Hanuman Satishchandra, Aralaguppe S Sridhar, Basavaradhya P PoojaJournal of Cancer Research and Therapeutics 2013 9(1):128-130Burkitt's lymphoma is an uncommon form of non-Hodgkin lymphoma in adults. The diagnostic workup for Burkitt's lymphoma includes radiological imaging and like any other form of non-Hodgkin's lymphoma definitive diagnosis is by histopathology. Imaging is necessary to determine the distribution and severity in terms of extent and organs of involvement to further assist in staging and thence to implement appropriate therapy. High incidence of intraabdominal involvement is seen in Am...
Source: Journal of Cancer Research and Therapeutics - April 10, 2013 Category: Cancer & Oncology Authors: Hanuman SatishchandraAralaguppe S SridharBasavaradhya P Pooja Source Type: research
Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation [Hematologic Malignancies]
Conclusion
R-BAC is well tolerated and active against MCL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 5, 2013 Category: Cancer & Oncology Authors: Visco, Finotto, Zambello, Paolini, Menin, Zanotti, Zaja, Semenzato, Pizzolo, D'Amore, Rodeghiero Tags: Combined Modality, Biologic Therapy Hematologic Malignancies Source Type: research
Alterations in serum immunoglobulin levels in workers occupationally exposed to trichloroethylene
Trichloroethylene (TCE) has been associated with a variety of immunotoxic effects and may be associated with an increased risk of non-Hodgkin lymphoma (NHL). Altered serum immunoglobulin (Ig) levels have been reported in NHL patients and in animals exposed to TCE. Recently, we reported that occupational exposure to TCE is associated with immunosuppressive effects and immune dysfunction, including suppression of B-cell counts and activation, even at relatively low levels. We hypothesized that TCE exposure would also affect Ig levels in humans. We measured serum levels of IgG, IgM and IgE, by enzyme-linked immunosorbent assa...
Source: Carcinogenesis - April 4, 2013 Category: Cancer & Oncology Authors: Zhang, L., Bassig, B. A., Mora, J. L., Vermeulen, R., Ge, Y., Curry, J. D., Hu, W., Shen, M., Qiu, C., Ji, Z., Reiss, B., McHale, C. M., Liu, S., Guo, W., Purdue, M. P., Yue, F., Li, L., Smith, M. T., Huang, H., Tang, X., Rothman, N., Lan, Q. Tags: Original Manuscript Source Type: research
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ~14% of DLBCL patients. Patients with CD30+ DLBCL had superior 5-year overall survival (CD30+, 79% vs CD30–, 59%; P = .001) and progression-free survival (P = ...
Source: Blood - April 4, 2013 Category: Hematology Authors: Hu, S., Xu-Monette, Z. Y., Balasubramanyam, A., Manyam, G. C., Visco, C., Tzankov, A., Liu, W.-m., Miranda, R. N., Zhang, L., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K. L., Hsi, E. D., Choi, W. W. L., Han van Kri Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
[Comment] Cancer control in Africa: which priorities?
Increased life expectancy and the continued presence of infectious diseases that are associated with risks of malignancies make cancer an increasing problem in sub-Saharan Africa. Survival from cancer in the region is very low, and only 5% of patients are estimated to receive chemotherapy. Most funds are spent on individual systemic treatments, even though many of the most common cancers in the continent (eg, Kaposi's sarcoma, cervical cancer, breast cancer, and some types of non-Hodgkin lymphoma) can be prevented or detected early and thus be treated. (Source: The Lancet Oncology)
Source: The Lancet Oncology - April 1, 2013 Category: Cancer & Oncology Authors: Sandro Vento Tags: Comment Source Type: research
An Integrated Computational/Experimental Model of Lymphoma Growth
by Hermann B. Frieboes, Bryan R. Smith, Yao-Li Chuang, Ken Ito, Allison M. Roettgers, Sanjiv S. Gambhir, Vittorio Cristini
Non-Hodgkin's lymphoma is a disseminated, highly malignant cancer, with resistance to drug treatment based on molecular- and tissue-scale characteristics that are intricately linked. A critical element of molecular resistance has been traced to the loss of functionality in proteins such as the tumor suppressor p53. We investigate the tissue-scale physiologic effects of this loss by integrating in vivo and immunohistological data with computational modeling to study the spatiotemporal physical dyna...
Source: PLoS Computational Biology - March 28, 2013 Category: Biology Authors: Hermann B. Frieboes et al. Source Type: research
Does standard intravenous calcium gluconate administration during peripheral blood stem cell collection reduce the chance of a citrate reaction?
To prevent blood clotting during stem cell collection Acid Citrate Dextrose- formula A (ACD-A) (Haemonetics) is given routinely in our center in a range of 1:12mL. Citrate in itself can cause common side effects such as tingling, parenthesis, nausea/vomiting and muscle cramps. These side effects can be treated by the administration of Calcium orally, or intravenously. In our center 179 procedures were performed in 142 patients from January 2009 until February. Patients were diagnosed with Non Hodgkin Lymphoma (NHL) 24, Multiple Myeloma (MM) 61,Hodgkin Lymphoma (HL) 18, Mantle cell Lymphoma (MCL) 18, Acute Myeloid Leukemia ...
Source: Transfusion and Apheresis Science - March 27, 2013 Category: Hematology Authors: J.D.J. Brunner-Spiering, M.E.B. Grootes, P.A.W. te Boekhorst, G.E. de Greef Tags: Guest Editorial Source Type: research
Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma
Cancer Biotherapy & Radiopharmaceuticals , Vol. 0, No. 0. (Source: Cancer Biotherapy and Radiopharmaceuticals)
Source: Cancer Biotherapy and Radiopharmaceuticals - March 26, 2013 Category: Cancer & Oncology Tags: article Source Type: research
Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines
The effective antitumorigenic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) and eicosonoid (EP; EP1-4) receptor antagonists prompted us to test their efficacy in Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) related lymphomas. Our study demonstrated that (1) EP1-4 receptor protein levels vary among the various non-Hodgkin’s lymphoma (NHL) cell lines tested (BCBL-1:KSHV+/EBV-;BC-3: KSHV+/EBV-; Akata/EBV+: KSHV-/EBV+; and JSC-1 cells: KSHV+/EBV + cells); (2) 5.0 μM of EP1 antagonist (SC-51322) had a significant antiproliferative effect on BCBL-1, BC-3, Akata/EBV+, and JSC-1 c...
Source: Translational Research - March 25, 2013 Category: Research Authors: Arun George Paul, Bala Chandran, Neelam Sharma-Walia Tags: Featured New Investigator Source Type: research
CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
Abstract: A phase I trial of infusing anti-CD3 × anti-CD20 bispecific antibody (CD20Bi) armed activated T cells (aATC) was conducted in high-risk/refractory non-Hodgkin's lymphoma patients to determine whether aATC infusions are safe, affect immune recovery, and induce an antilymphoma effect. Ex vivo expanded ATC from 12 patients were armed with anti-CD20 bispecific antibody, cryopreserved, and infused after autologous stem cell transplantation (SCT). Patients underwent SCT after high-dose chemotherapy, and aATC infusions were started on day +4. The patients received 1 infusion of aATC per week for 4 weeks after SCT wi...
Source: Biology of Blood and Marrow Transplantation - March 25, 2013 Category: Hematology Authors: Lawrence G. Lum, Archana Thakur, Qin Liu, Abhinav Deol, Zaid Al-Kadhimi, Lois Ayash, Muneer H. Abidi, Cassara Pray, Elyse N. Tomaszewski, Patricia A. Steele, Dana L. Schalk, Hiroshi Yano, Alice Mitchell, Melissa Dufresne, Joseph P. Uberti, Voravit Ratanat Tags: Clinical Research Source Type: research
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and rituximab (R)–CHOP treated patients. We investigated the prognostic relevance of MYC-, BCL2- and BCL6-rearrangements and protein expression in a prospective randomized trial. Paraffin-embedded tumor samples from 442 de novo DLBCL treated within the RICOVER study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) were investigated using immunohistochemistry and fluorescence in situ hybridization (FISH) to detect protein...
Source: Blood - March 21, 2013 Category: Hematology Authors: Horn, H., Ziepert, M., Becher, C., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.-L., Schmelter, C., Moller, P., Cogliatti, S., Pfreundschuh, M., Schmitz, N., Trumper, L., Siebert, R., Loeffler, M., Rosenwal Tags: Free Research Articles, Lymphoid Neoplasia Source Type: research
Researchers Say NSAIDs Can Boost Stem Cells For Transplants For Cancer Patients
Scientists say that non-steroidal anti-inflammatory drugs may be a boon to doctors gathering stem cells for transplants to treat patients with blood or bone marrow cancers, including non-Hodgkin's lymphoma and multiple myeloma. The compounds, known as NSAIDs and which include aspirin, ibuprofen and other painkillers, increased the number of stem and progenitor cells harvested from the blood in animal testing and a small human study, according to work published online Wednesday in the journal Nature by a research team led by Indiana University School of Medicine scientists... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news
The insulin-like growth factor-system in a patient with diffuse large B-cell non-Hodgkin's lymphoma and lactic acidosis
We present a case of a 79-year-old man with a diffuse large B-cell lymphoma and lactic acidosis. Initially, the patient was successfully treated according to the R-CHOP scheme. After recurrence of disease, the patient was treated according to a protocol of the Dutch-Belgian Haemato-Oncology Group (HOVON-85 study). Eleven months after completion of the last therapy, the patient still appeared to be in complete remission. Serum levels of IGFs, pro-IGF-IIE[68–88], IGF binding proteins (IGFBPs)-1 to -4, acid labile subunit (ALS), as well as ternary IGF-I-IGFBP-3-ALS complex formation, were determined in samples taken bef...
Source: Annals of Clinical Biochemistry - March 19, 2013 Category: Biochemistry Authors: Hoogwerf, D., van Doorn, J., Maartense, E. Tags: Case Reports Source Type: research
Non-Hodgkin lymphoma as an uncommon cause of acute heart failure
MSM, homem, 69 anos, procurou atendimento médico por dor em dorso esquerdo e membro inferior direito. A radiografia de tórax revelou alargamento do mediastino. Estava em observação quando apresentou rebaixamento da consciência e choque. Foi observado enfisema subcutâneo em hemitórax esquerdo e abolição do murmúrio vesicular em base do mesmo pulmão. Foi feita a intubação orotraqueal e realizada drenagem de hemitórax esquerdo, com saída de líquido serossanguinolento. O ecocardiograma revelou ventrículo esquerdo (D/S): 44/29 mm; septo 12 mm; parede posterior 13 mm; discreta dilatação em raiz da aorta, prese...
Source: Arquivos Brasileiros de Cardiologia - March 15, 2013 Category: Cardiology Source Type: research
Transformation from follicular lymphoma to biphasic high-grade large B-cell lymphoma with immunophenotypically and genetically distinct diffuse large B cell and Burkitt-like components
Transformation of follicular lymphoma (FL) into high-grade B-cell non-Hodgkin lymphoma, usually diffuse large B-cell lymphoma (DLBCL), occurs in 25–35% of patients.1 This transformation has been shown to occur as a result of gain of MYC (8q24) rearrangement in addition to the t(14;18)(q32;q21), leading to a ‘double-hit’ lymphoma.2–10 Indeed, 5% of all FL with a BCL2 breakpoint will acquire a MYC rearrangement during the course of the disease.2 Double-hit lymphomas with MYC and BCL2 rearrangements have overexpression of BCL2 (a potent anti-apoptotic protein) and MYC (an enhancer of cell proliferation...
Source: Journal of Clinical Pathology - March 14, 2013 Category: Pathology Authors: Dunn, R. G., Foot, N. J., Ffolkes, L., Newell, B., Wilkins, B. S., Neat, M. J. Tags: PostScript Source Type: research
[Lymphoma and arteries: Peri- or intravascular?]
CONCLUSION: The distinction between perivascular and intravascular arterial involvement is based on a range of features and is essential for an optimal care of patients with lymphoma.
PMID: 23473620 [PubMed - as supplied by publisher] (Source: Journal des Maladies Vasculaires)
Source: Journal des Maladies Vasculaires - March 6, 2013 Category: Cardiology Authors: Franz M, Alfidja A, Molucon Chabrot C, Hermet E, Montoriol PF, Rosset E, Boyer L, Chabrot P Tags: J Mal Vasc Source Type: research
Demographic and disease characteristics associated with non-hodgkin lymphoma survivors' quality of life: does age matter?
Conclusions: Age was a moderator for income and an indicator for how income could affect care of younger survivors. Men reported a lower QOL than women and gender-specific resources may be helpful to them.Implications for Nursing: Nursing research should focus on age-sensitive resources targeted for younger NHL survivors.Knowledge Translation: Age is an important characteristic that impacts overall health-related QOL. Oncology nurses are instrumental in identifying patients at all ages who could benefit from age-specific resources.
PMID: 23448740 [PubMed - in process] (Source: Oncology Nursing Forum)
Source: Oncology Nursing Forum - March 1, 2013 Category: Nursing Authors: Leak A, Smith SK, Crandell J, Jenerette C, Bailey DE, Zimmerman S, Mayer DK Tags: Oncol Nurs Forum Source Type: research
The relationship between learned resourcefulness and cancer-related fatigue in patients with non-hodgkin lymphoma.
Conclusions: The findings showed a negative correlation between a physiologic variable (fatigue) and a psychological variable (learned resourcefulness), which is related to individual coping ability.Implications for Nursing: Nurses should receive education about learned resourcefulness to potentially help patients with cancer cope with chemotherapy-related fatigue.Knowledge Translation: As learned resourcefulness was negatively correlated with chemotherapy-related fatigue in patients with NHL, having this personality trait may help those patients manage fatigue.
PMID: 23448738 [PubMed - in process] (Source: Oncology Nursing Forum)
Source: Oncology Nursing Forum - March 1, 2013 Category: Nursing Authors: Menshadi N, Bar-Tal Y, Barnoy S Tags: Oncol Nurs Forum Source Type: research
Trends in Post-Treatment Leukemia
The risks of chemotherapy-related acute myeloid leukemia have changed significantly over the last 30 years, increasing in people treated for non-Hodgkin's lymphoma and decreasing in people treated for... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 28, 2013 Category: Cancer & Oncology Source Type: news
Treatment-Related AML Rises in Non-Hodgkin's Lymphoma
The risks of chemotherapy-related acute myeloid leukemia have changed significantly over the last 30 years, increasing in people treated for non-Hodgkin's lymphoma and decreasing in people treated for... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 26, 2013 Category: Cancer & Oncology Source Type: news
Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial [Cancer-Related Complications]
Conclusion
Approximately 20% of patients in both groups exhibited POF after 1 year of follow-up. Triptorelin was not associated with a significant decreased risk of POF in young patients treated for lymphoma but may provide protection of the ovarian reserve. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 25, 2013 Category: Cancer & Oncology Authors: Demeestere, Brice, Peccatori, Kentos, Gaillard, Zachee, Casasnovas, Van Den Neste, Dechene, De Maertelaer, Bron, Englert Tags: Menopausal Symptoms, Chemotherapy, Quality of Life Cancer-Related Complications Source Type: research
High Familial Risk in Nodular Lymphocyte-Predominant Hodgkin Lymphoma [Hematologic Malignancy]
Conclusion
Our results implicate an unexpectedly high familial component in the development of NLPHL. Research is warranted to identify the putative genetic and environmental factors underlying this finding and to develop strategies for better management of patients with NLPHL and their relatives. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 25, 2013 Category: Cancer & Oncology Authors: Saarinen, Pukkala, Vahteristo, Makinen, Franssila, Aaltonen Tags: Epidemiology Hematologic Malignancy Source Type: research
Methotrexate: Non-Hodgkin's lymphoma and recurrent lymphoproliferative disorder: case report
(Source: Reactions)
Source: Reactions - February 24, 2013 Category: Drugs & Pharmacology Tags: Short communication Source Type: research
Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell Lymphoma
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1 Median PFS for patients treated with B-R was 69... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

